Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 239

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 239
---
 Shiff’s extensive experience in the pharmaceutical industry as a leader in the development and implementation of evidence, access, and pricing strategies for products globally provides her with the qualifications to serve on our board of directors.

#### Family Relationships
There are no family relationships among any of our directors or executive officers.

#### Board of Directors
Our business and affairs are organized under the direction of the Board. The Board currently consists of six directors divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three-year term. Sujal Shah serves as Chairman of our Board. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling and direction to our management. The Board will meet on a regular basis and additionally as required.

In accordance with the terms of the Company’s amended certificate of incorporation and the amended bylaws, the Board is divided into three classes, Class I, Class II and Class III, with members of each class serving staggered three-year terms. The members of the classes are divided as follows:

•

the Class I directors are Susan Shiff and Michael Wyzga, and their terms will expire at the annual meeting of stockholders to be held in 2028;

•

the Class II directors are Imran Alibhai, Cynthia Smith and Sujal Shah, and their terms will expire at the annual meeting of stockholders to be held in 2026; and

•

the Class III director is Wallace Hall, and his terms will expire at the annual meeting of stockholders to be held in 2027.

In accordance with the terms of the Merger Agreement, our board of directors consists of one member designated by Cara, who is Susan Shiff, Ph.D., and five members designated by Legacy Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Imran Alibhai, Ph.D., and Cynthia Smith.

#### Director Independence
Under the Nasdaq Listing Rules, a majority of the members of the board of directors must qualify as “independent,” as affirmatively determined by the board of directors. Under the Nasdaq Listing Rules, a director will only qualify as an “independent director” if, in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Company’s board of directors has determined that each of its directors other than Dr. Alibhai qualify as “independent directors” as defined